Viewpoint: Pediatric CML: Life-Long Considerations With TKI Therapy
View web version
mAb Therapies for Multiple Myeloma
Daratumumab is moving from a monotherapy for relapsed and refractory myeloma to a potential frontline player in combination induction regimens. And on the horizon are investigational bispecific antibodies, mAb-drug conjugates, and CAR-T therapies that might offer new advances against what today remains an incurable disease.
Pediatric CML: Life-Long Considerations With TKI Therapy
Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.
Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC
The phase 3 study found the combination effective, regardless of tumor proportion score.
Latest News
Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer
Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC
Noninvasive Exhaled Breath Test May Be Effective In Diagnosing Esophagogastric Cancers

Want to receive emails specific to your profession and specialty? Click here to complete your profile.

If you were sent this by a colleague and wish to subscribe to Daily Update, please click here.

To unsubscribe from Daily Update click here.
To update your email preferences click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

© 2018 Haymarket Media Inc | 275 7th Avenue, 10th Floor | New York, NY 10001